. | . |
Drug discovery and development - in space by Staff Writers Washington DC (SPX) Nov 18, 2022
Carrying out scientific experiments in space allows scientists to study and make drugs without gravity, which can lead to surprising results that improve research back on Earth. According to a cover story in Chemical and Engineering News, an independent news outlet of the American Chemical Society, more commercial entities are expanding offerings in low-Earth orbit, which could someday enable more common and affordable drug discovery and manufacture in space. The low-gravity environment on the International Space Station (ISS) can speed up the development and discovery of complex molecules used in medicines, writes Assistant Editor Shi En Kim. Misbehaving proteins are the culprit behind many diseases, so scientists will often crystallize a protein to better understand its complex structure. When carried out in space, this process can produce larger and more uniform crystals than those grown on Earth. Protein crystallization experiments in microgravity have been instrumental in the design of some cancer drugs. Additionally, because the effects of space travel on the body resemble those of aging, scientists have taken advantage of the unique environment to study aging treatments, including carrying out preclinical trials of two now-approved osteoporosis drugs. In the future, stem cell therapy research could benefit from observations that stem cells can grow more quickly in space. Currently, access to the ISS for experiments is limited - and competition to get experiments onboard is fierce. It often takes years to prepare for an experiment, and once scientists have results, it could be another several years before they have access again. The ISS is slated to retire in less than a decade, but the rise of the commercialization of space means that researchers may someday have more opportunities to carry out experiments or manufacture drugs in this environment at potentially lower costs. Private companies, such as SpaceX, Northrup Grumman and Blue Origin, are building commercial stations to replace the ISS, and we could be seeing more experiments being performed in orbit with profound impacts on science back on Earth. Video: Pharma goes to space
An easier way to remove medical devices Boston MA (SPX) Nov 09, 2022 By taking advantage of a phenomenon that leads to fractures in metal, MIT researchers have designed medical devices that could be used inside the body as stents, staples, or drug depots, then safely broken down on demand when they're no longer needed. The researchers showed that biomedical devices made from aluminum can be disintegrated by exposing them to a liquid metal known as eutectic gallium-indium (EGaIn). In practice, this might work by painting the liquid onto staples used to hold skin tog ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |